Site Map Press Room Careers
Financial
Quarterly Results
Financial Highlights
Annual Reports
Business Drivers
Investors
Contact Person
Frequently Asked Questions

Unaudited Quarterly Results for the Quarter & Half year ended 30th September, 2004

(Rs. in Mio)
  Three Months Ended Six Months Ended Year ended

Particulars

 (Unaudited) (Unaudited) (Audited)
  30.09.2004 30.09.2003 30.09.2004 30.09.2003 31.03.2004
Net Sales/Income from Operations 2693.1 3489.9 5542.4 6548.6 13410.7
Other Income 26.7 38.9 50.3 56.3

220.6
Total Income 2719.8 3528.8 5592.7 6604.9 13631.3
Expenditure          
a. (Increase) / Decrease in Stock in Trade
51.0 (82.6) (183.6) (258.1) (363.5)
 b. Consumption of Raw Materials 1423.4 2076.0 3134.3 4146.6 7913.5
 c. Staff Cost 171.7 120.0 331.2 231.5 513.5
 d. Other Expenditure 800.1 795.8 1616.8 1415.7 3178.5
Total expenditure 2446.2 2909.2 4898.7 5535.1 11242.0
Profit Before Depreciation, Interest& Tax 273.6 619.6 694.0 1069.8 2389.3
Interest 101.8 99.6 175.4 159.6 322.5
Depreciation 122.4 83.9 232.2 154.6 341.6
Profit before taxation 49.4 436.1 286.4 755.6 1725.2
Provision for Taxation
a) Current Tax
b) Deferred Tax
c) Tax adjustments of previous years
7.4
7.5
8.9
66.5
48.1
--
25.2
46.2
9.2
136.4
67.2
--
292.7
161.5
0.8
Net Profit 25.6 321.5 205.8 552.0 1270.2
Paid-up Equity Share Capital 
(Face value Rs. 5/- per share)		 253.9 242.0 253.9 242.0 253.9
Reserves excluding Revaluation Reserves -- -- -- -- 7309.9
Earnings per share (Rs.) (not annualised)          
- Basic
0.50  6.83 3.55 11.80 26.54
-Diluted
0.50 6.78 3.55 11.69 26.41
Aggregate of non-promoters Shareholding          
a.Number of Shares     22935706 19383470 22942230
b. Percentage of Shareholding     45.18  40.05 45.19
Notes:
1. The above unaudited results which are subjected to limited review by the Auditors of the Company, were reviewed by the Audit Committee and have been taken on record by the Board at its meeting held on 29.10.2004.
2. The Company has completely written off expenses pertaining to R & D, Regulatory Plants and Bioequivalence Studies which affected the profitability in short term whereas the revenues from the regulated markets are expected in future.
3. Exports (F.O.B value) constitute Rs.1250.4 millions (Rs.1598.1 millions) of the sales for the quarter.
4. The Company's operations fall within a single primary business segment viz 'Pharmaceutical Products'.
5. Investor  complaints  pending  at  the  beginning  of  the  quarter: Nil,  received: 124,  resolved: 124 and lying unresolved at the end of the quarter: Nil. 
6. Figures for the previous periods have been rearranged/regrouped wherever necessary.
For and on behalf of the Board
Sd/-
Place: Hyderabad K.Nityananda Reddy
Date : 29.10.2004 Managing Director
Site Map Press Room Careers